Use of bivalirudin as an anticoagulant during cardiopulmonary bypass

Journal of Extra-Corporeal Technology

Volumn 37, Issue 3, 2005, Pages 296-302

  Veale, James J ^a   McCarthy, Harry M ^b   Palmer, George ^c   Dyke, Cornelius M ^a  

^a Gaston Memorial Hospital   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Central Florida Regional Hospital   (United States)

Author keywords

Anticoagulation; Cardiopulmonary bypass; Direct thrombin inhibitors; heparin induced thrombocytopenia

Indexed keywords

ABCIXIMAB; ANTICOAGULANT AGENT; APROTININ; EPTIFIBATIDE; HEPARIN; HIRULOG; THROMBIN INHIBITOR;

BLEEDING; CARDIOPULMONARY BYPASS; CLINICAL TRIAL; DOSE RESPONSE; DRUG MONITORING; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; OFF PUMP CORONARY SURGERY; REVIEW; SURGICAL TECHNIQUE; TECHNIQUE; TREATMENT OUTCOME;

EID: 31544458190     PISSN: 00221058     EISSN: 29698960     Source Type: Journal    
DOI: None     Document Type: Review

References (19)

1. Warkentin TE, Levine MN, Hirsh J, et al. Heparin-induced thrombocytopenia in patients treated with low molecular-weight heparin or unfractionated heparin. N Engl J Med. 1995;332:1330-5.
2. Trossaert M, Gaillard A, Commin PL, Amiral J, Vissac AM, Fressinaud E. High incidence of anti-heparin/platelet factor 4 antibodies after cardiolpulmonary bypass surgery. Br J Hacmatol. 1998;101:653-5.
3. Pouplard C, May MA, Iochmann S, et al. Antibodies to platelet factor 4-heparin after cardiopulmonary bypass in patients anticoagulated with unfractionated heparin or a low molecular-weight heparin: Clinical implications for heparin-induced thrombocytopenia. Circulation. 1999;99:2530-6.
4. Mattioli AV, Bonetti L, Sternieri S, Mattioli G. Heparin-induced thrombocytopenia in patients treated with unfractionated heparin: Prevalence of thrombosis in a 1 year follow-up. Italian Heart J. 2000;1:39-42.
5. Mascelli MA, Deliargyris EN, Damaraju LV, Barnathan ES, Sane DC. Role of anti-PF4/heparin antibodies in recurrent thrombotic events after acute coronary syndromes. Semin Thromb Hemost. 2004;30:347-50.
6. Slaughter TF, Bennett-Guerrero E, Su Z, et al. Antiheparin/PF4 antibodies detected prior to cardiac surgery identify patients at high risk for adverse perioperative outcomes. Anesth Analg. 2002;93:SCA28.
7. Longrois D, de Maistre E, Bischoff N, et al. Recombinant hirudin anticoagulation for aortic valve replacement in heparin-induced thrombocytopenia. Can J Anaesth. 2000;47:255-60.
8. Vasquez JC, Vichiendilokkul A, Mahmood S, et al. Anticoagulation with bivalirudin during cardiopulmonary bypass in cardiac surgery. Ann Thorac Surg. 2002;74:2177-9.
9. Davis Z, Anderson R, Short D, et al. Favorable outcome with bivalirudin anticoagulation during cardiopulmonary bypass. Ann Thorac Surg. 2003;75:264-5.
10. Gordon G, Rastegar H, Schumann R, Deiss-Shrem J, Denman W. Successful use of bivalirudin for cardiopulmonary bypass in a patient with heparin-induced thrombocytopenia. J Cardiothorac Vasc Anesth. 2003;17:632-5.
11. Clayton SB, Acsell JR, Crumbley AJ, Uber WE. Cardiopulmonary bypass with bivalirudin in type II heparin-induced thrombocytopenia. Ann Thorac Surg. 2004;78:2167-9.
12. Dyke CM, Koster A, Veale JJ, Maier GW, McNiff T, Levy MD. Preemptive use of bivalirudin for urgent on-pump coronary artery bypass grafting in patients with potential heparin-induced thrombocytopenia. Ann Thorac Surg. 2005;80:299-303.
13. Koster A, Spiess B, Chew D. Effectiveness of bivalirudin as a replacement for heparin during cardiopulmonary bypass in patients undergoing coronary artery bypass grafting. Am J Cardiol. 2004;93:356-9.
14. Bittl JA, Chaitman B, Feit F, et al. Bivalirudin versus heparin during coronary angioplasty for unstable or postinfarction angina: Final report reanalysis of the Bivalirudin Angioplasty Study. Am Heart J. 2001;142:952-9.
15. Angiomax Package Insert, The Medicines Company, Parsippany, NJ.
16. Merry AF, Raudkivi PJ, Middleton NJ, McDougall JM, Nand P, Mills BP, et al. Bivalirudin versus heparin and protamine in off-pump coronary artery bypass surgery. Ann Thorac Surg. 2004;77:925-31.
17. Palmer George. Personal Communication.
18. The Medicines Company. Protocol No. TMC-BIV-02-06. A Study Comparing Angiomax® (Bivalirudin) to Heparin with Protamine Reversal in Patients Undergoing Cardiac Surgery.
19. Koster A, Yeter A, Buz S, et al. Hemostatic activation during normothermic cardiopulmonary bypass with bivalirudin: Results of the second pilot study to assess "on-pump" coronary artery bypass grafting with bivalirudin. J Thorac Cardiovasc Surg. 2005;129:1391-4.